Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman(University of Toronto), Ivan Pećin, J. Wouter Jukema(Leiden University Medical Center), Deepak L. Bhatt(Mount Sinai Hospital), Rafael Díaz(Estudios Clínicos Latinoamérica), Geneviève Garon(Sanofi (Canada)), Patricio López‐Jaramillo(Universidad De Santander), Robert Pordy(Inserm), Vera Bittner(University of Alabama at Birmingham), Yann Poulouin, Robert A. Harrington(Clinical Research Institute), Andreas M. Zeiher(Goethe University Frankfurt), Rafael Dı́az(Instituto Cardiovascular de Rosario), Harvey D. White(University of Auckland), Nina Gotcheva, Juan Carlos Prieto, Gregory G. Schwartz(University of Colorado Denver), Michael Szarek(St. Michael's Hospital), Heinz Drexel(ESCP Business School), Garen Manvelian(Regeneron (United States)), Pierluigi Tricoci(Duke University), Corinne Hanotin(Sanofi (France)), Mirza Dilić(Duke University), Jay M. Edelberg(Inserm), Angèle Moryusef(Inserm), William J. Sasiela(Inserm), Guillaume Lecorps(Sanofi (United States)), Matthew T. Roe(Inserm), Jean‐François Tamby(Medical University of South Carolina), Wanda Stipek(Regeneron (United States)), Huo Yong, Philippe Gabríel Steg(Mount Sinai Hospital)
European Heart Journal - Cardiovascular Pharmacotherapy
April 20, 2024
Cited by 24


Related Papers